| Dr Gustavo F Tataje Rengifo, MD | |
|
3955 Patient Care Dr Ste A, Lansing, MI 48911 | |
| (517) 374-7600 | |
| Not Available |
| Full Name | Dr Gustavo F Tataje Rengifo |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 10 Years |
| Location | 3955 Patient Care Dr Ste A, Lansing, Michigan |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033601489 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 4351043487 (Michigan) | Secondary |
| 207R00000X | Internal Medicine | 4301504688 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mclaren Greater Lansing | Lansing, MI | Hospital |
| Edward W Sparrow Hospital | Lansing, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Eaton Rapids Medical Center | 5991692634 | 21 |
| Edward W Sparrow Hospital Association | 6709799166 | 522 |
| Capital Internal Medicine Associates P.c. | 8022097963 | 63 |
News Archive
Researchers have discovered a strong link between genetic changes known to cause neurodevelopmental disabilities and cerebral palsy.
Today, the U.S. Food and Drug Administration approved a new indication for Myrbetriq (mirabegron extended-release tablets) and Myrbetriq Granules (mirabegron for extended-release oral suspension) to treat neurogenic detrusor overactivity (NDO), a bladder dysfunction related to neurological impairment, in children ages three years and older.
Egocentric, self-centred, and insensitive to the needs of others: these social problems often arise in people with severe traumatic brain injury (TBI) and have been attributed in part to a loss of emotional empathy, the capacity to recognise and understand the emotions of other people.
Tumor volume in a preclinical model of triple negative breast cancer (TNBC) was reduced four times more when an experimental polo-like kinase 1 (PLK1) inhibitor was combined with a standard-of-care chemotherapeutic agent than when the agent was used alone.
› Verified 7 days ago
| Entity Name | Eaton Rapids Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1588810709 PECOS PAC ID: 5991692634 Enrollment ID: O20040301000307 |
News Archive
Researchers have discovered a strong link between genetic changes known to cause neurodevelopmental disabilities and cerebral palsy.
Today, the U.S. Food and Drug Administration approved a new indication for Myrbetriq (mirabegron extended-release tablets) and Myrbetriq Granules (mirabegron for extended-release oral suspension) to treat neurogenic detrusor overactivity (NDO), a bladder dysfunction related to neurological impairment, in children ages three years and older.
Egocentric, self-centred, and insensitive to the needs of others: these social problems often arise in people with severe traumatic brain injury (TBI) and have been attributed in part to a loss of emotional empathy, the capacity to recognise and understand the emotions of other people.
Tumor volume in a preclinical model of triple negative breast cancer (TNBC) was reduced four times more when an experimental polo-like kinase 1 (PLK1) inhibitor was combined with a standard-of-care chemotherapeutic agent than when the agent was used alone.
› Verified 7 days ago
| Entity Name | Capital Internal Medicine Associates P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780629832 PECOS PAC ID: 8022097963 Enrollment ID: O20040715000369 |
News Archive
Researchers have discovered a strong link between genetic changes known to cause neurodevelopmental disabilities and cerebral palsy.
Today, the U.S. Food and Drug Administration approved a new indication for Myrbetriq (mirabegron extended-release tablets) and Myrbetriq Granules (mirabegron for extended-release oral suspension) to treat neurogenic detrusor overactivity (NDO), a bladder dysfunction related to neurological impairment, in children ages three years and older.
Egocentric, self-centred, and insensitive to the needs of others: these social problems often arise in people with severe traumatic brain injury (TBI) and have been attributed in part to a loss of emotional empathy, the capacity to recognise and understand the emotions of other people.
Tumor volume in a preclinical model of triple negative breast cancer (TNBC) was reduced four times more when an experimental polo-like kinase 1 (PLK1) inhibitor was combined with a standard-of-care chemotherapeutic agent than when the agent was used alone.
› Verified 7 days ago
| Entity Name | Edward W Sparrow Hospital Association |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437331501 PECOS PAC ID: 6709799166 Enrollment ID: O20080219000111 |
News Archive
Researchers have discovered a strong link between genetic changes known to cause neurodevelopmental disabilities and cerebral palsy.
Today, the U.S. Food and Drug Administration approved a new indication for Myrbetriq (mirabegron extended-release tablets) and Myrbetriq Granules (mirabegron for extended-release oral suspension) to treat neurogenic detrusor overactivity (NDO), a bladder dysfunction related to neurological impairment, in children ages three years and older.
Egocentric, self-centred, and insensitive to the needs of others: these social problems often arise in people with severe traumatic brain injury (TBI) and have been attributed in part to a loss of emotional empathy, the capacity to recognise and understand the emotions of other people.
Tumor volume in a preclinical model of triple negative breast cancer (TNBC) was reduced four times more when an experimental polo-like kinase 1 (PLK1) inhibitor was combined with a standard-of-care chemotherapeutic agent than when the agent was used alone.
› Verified 7 days ago
| Entity Name | Edward W Sparrow Hospital Association |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043562465 PECOS PAC ID: 6709799166 Enrollment ID: O20130503000582 |
News Archive
Researchers have discovered a strong link between genetic changes known to cause neurodevelopmental disabilities and cerebral palsy.
Today, the U.S. Food and Drug Administration approved a new indication for Myrbetriq (mirabegron extended-release tablets) and Myrbetriq Granules (mirabegron for extended-release oral suspension) to treat neurogenic detrusor overactivity (NDO), a bladder dysfunction related to neurological impairment, in children ages three years and older.
Egocentric, self-centred, and insensitive to the needs of others: these social problems often arise in people with severe traumatic brain injury (TBI) and have been attributed in part to a loss of emotional empathy, the capacity to recognise and understand the emotions of other people.
Tumor volume in a preclinical model of triple negative breast cancer (TNBC) was reduced four times more when an experimental polo-like kinase 1 (PLK1) inhibitor was combined with a standard-of-care chemotherapeutic agent than when the agent was used alone.
› Verified 7 days ago
| Entity Name | Edward W Sparrow Hospital Association |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1487154290 PECOS PAC ID: 6709799166 Enrollment ID: O20180405001766 |
News Archive
Researchers have discovered a strong link between genetic changes known to cause neurodevelopmental disabilities and cerebral palsy.
Today, the U.S. Food and Drug Administration approved a new indication for Myrbetriq (mirabegron extended-release tablets) and Myrbetriq Granules (mirabegron for extended-release oral suspension) to treat neurogenic detrusor overactivity (NDO), a bladder dysfunction related to neurological impairment, in children ages three years and older.
Egocentric, self-centred, and insensitive to the needs of others: these social problems often arise in people with severe traumatic brain injury (TBI) and have been attributed in part to a loss of emotional empathy, the capacity to recognise and understand the emotions of other people.
Tumor volume in a preclinical model of triple negative breast cancer (TNBC) was reduced four times more when an experimental polo-like kinase 1 (PLK1) inhibitor was combined with a standard-of-care chemotherapeutic agent than when the agent was used alone.
› Verified 7 days ago
| Entity Name | Sparrow Specialty Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437655842 PECOS PAC ID: 2466347638 Enrollment ID: O20180607002998 |
News Archive
Researchers have discovered a strong link between genetic changes known to cause neurodevelopmental disabilities and cerebral palsy.
Today, the U.S. Food and Drug Administration approved a new indication for Myrbetriq (mirabegron extended-release tablets) and Myrbetriq Granules (mirabegron for extended-release oral suspension) to treat neurogenic detrusor overactivity (NDO), a bladder dysfunction related to neurological impairment, in children ages three years and older.
Egocentric, self-centred, and insensitive to the needs of others: these social problems often arise in people with severe traumatic brain injury (TBI) and have been attributed in part to a loss of emotional empathy, the capacity to recognise and understand the emotions of other people.
Tumor volume in a preclinical model of triple negative breast cancer (TNBC) was reduced four times more when an experimental polo-like kinase 1 (PLK1) inhibitor was combined with a standard-of-care chemotherapeutic agent than when the agent was used alone.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Gustavo F Tataje Rengifo, MD 3955 Patient Care Dr Ste A, Lansing, MI 48911-4271 Ph: (517) 374-7600 | Dr Gustavo F Tataje Rengifo, MD 3955 Patient Care Dr Ste A, Lansing, MI 48911 Ph: (517) 374-7600 |
News Archive
Researchers have discovered a strong link between genetic changes known to cause neurodevelopmental disabilities and cerebral palsy.
Today, the U.S. Food and Drug Administration approved a new indication for Myrbetriq (mirabegron extended-release tablets) and Myrbetriq Granules (mirabegron for extended-release oral suspension) to treat neurogenic detrusor overactivity (NDO), a bladder dysfunction related to neurological impairment, in children ages three years and older.
Egocentric, self-centred, and insensitive to the needs of others: these social problems often arise in people with severe traumatic brain injury (TBI) and have been attributed in part to a loss of emotional empathy, the capacity to recognise and understand the emotions of other people.
Tumor volume in a preclinical model of triple negative breast cancer (TNBC) was reduced four times more when an experimental polo-like kinase 1 (PLK1) inhibitor was combined with a standard-of-care chemotherapeutic agent than when the agent was used alone.
› Verified 7 days ago
Aline De Quadros Teixeira, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 1200 E Michigan Ave Ste 500, Lansing, MI 48912 Phone: 517-364-5184 | |
Dr. Harry James Mccoy, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 1540 Lake Lansing Rd, Ste 201, Lansing, MI 48912 Phone: 517-913-3900 Fax: 517-913-3901 | |
Ali H. Sheikh, D.O Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1140 E Michigan Ave Ste 400, Lansing, MI 48912 Phone: 517-364-9650 Fax: 517-364-9605 | |
Georgette Nader, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 1215 E Michigan Ave, Lansing, MI 48912 Phone: 517-253-8366 | |
Salma Mohamed, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 1215 E Michigan Ave, Lansing, MI 48912 Phone: 517-364-1000 | |
Dr. Cynthia S. Boynton, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 1540 Lake Lansing Rd, Ste 201, Lansing, MI 48912 Phone: 517-913-3900 Fax: 517-913-3901 | |
Fadi Mohammadsaeed S Alreefi, M.D Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 1140 E Michigan Ave Ste 400, Lansing, MI 48912 Phone: 419-921-2531 Fax: 517-364-9605 |